Achillion Pharmaceuticals

Achillion Pharmaceuticals (NASDAQ: ACHN) is a science-driven, patient-focused company dedicated to leveraging its strengths across the entire process from drug discovery to commercialization, with the goal of providing better treatments for patients with serious diseases. The company employs a highly disciplined approach to discovery and development, enabling it to pursue optimal therapies for chronic hepatitis C (HCV) and establish a platform for potent and specific complement factor D inhibitors. Achillion is rapidly advancing its efforts to become a fully integrated pharmaceutical company, with the aim of delivering life-saving drugs to patients with rare diseases.